Tumour necrosis factor (TNF)-inhibitors including etanercept (ETN) are effective for the treatment of RA [7], with TNF-α being a well-recognised contributor to the inflammatory changes that occur in RA [8, 9]. This evidence concerns the gene TNF and rheumatoid arthritis.